XRAY Dentsply Sirona
- 28.480
- +0.230+0.81%
Dentsply Sirona News
Goldman Sachs: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from neutral to neutral, and adjusted the target price from $34.00 to $30.00.
Goldman Sachs Maintains Neutral on Dentsply Sirona, Lowers Price Target to $30
Dentsply Sirona Analyst Ratings
Evercore ISI Group: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $40.00 to $35.00.
Dentsply Sirona Analyst Ratings
Evercore ISI Group Maintains Outperform on Dentsply Sirona, Lowers Price Target to $35
UBS Adjusts Price Target on Dentsply Sirona to $37 From $38, Maintains Buy Rating
DENTSPLY SIRONA: A Buy Rating With Positive Long-Term Growth Prospects Despite Short-Term Challenges
Challenging Growth and Market Pressures Lead to Hold Rating for DENTSPLY SIRONA
Dentsply Sirona Analyst Ratings
Needham Maintains Buy on Dentsply Sirona, Lowers Price Target to $36
Needham: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from buy to buy rating, and adjusted the target price from $42.00 to $36.00.
Barrington Research: Maintaining the Dentsply Sirona (XRAY.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $41.00 to $41.00.
Dentsply Sirona Analyst Ratings
Barrington Research Maintains Outperform on Dentsply Sirona, Maintains $41 Price Target
DENTSPLY SIRONA: Strong Growth and Efficiency Gains Signal Outperform Rating
Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), DENTSPLY SIRONA (XRAY) and Karuna Therapeutics (KRTX)
Dentsply Sirona Analyst Ratings
Analysts Conflicted on These Healthcare Names: DENTSPLY SIRONA (XRAY), Xenon (XENE) and Oric Pharmaceuticals (ORIC)
DENTSPLY SIRONA: A Buy Rating Amid Dental Downturn, Outperforming With Strong Q4 Results and Promising FY24 Guidance
Analysis
Price Target
No Data
